What the changes say
- The company discontinued development after NEAT results and is now focused on strategic alternatives, including a possible reverse merger.
- Liquidity has become critical: Nasdaq noncompliance, substantial going-concern doubt, potential bankruptcy, and continued losses dominate the new risks.
- Legacy eDSP obligations, third-party compliance, intellectual-property protection, and possible shell-company status remain material despite reduced operating activity.
What changed since the prior 10-K
New
- NewRisks Relating to Our Business and Financial Condition
Nasdaq may delist our securities from its exchange, which could adversely affect our ability to execute a strategic transaction and limit our stockholders’ liquidity
Nasdaq warned of failures involving the $1.00 bid price and $50 million market value requirements, threatening delisting, liquidity, financing, and strategic transactions.
- NewRisks Relating to Our Business and Financial Condition
requirements, there is no guarantee that we will be able to regain compliance. In addition, as of December 31, 2025, our total stockholders’ deficit was approximately $35.7 million
- NewRisks Relating to Our Business and Financial Condition
If we are unable to execute a strategic transaction, may be required to pursue a reorganization proceeding under applicable bankruptcy or insolvency laws, including under Chapters 7 or 11 of the U.S. Bankruptcy Code
Failure to complete a strategic transaction could trigger EIB loan acceleration and require Chapter 7 or 11 proceedings, leaving common stockholders little or no value.
- NewRisks Relating to Our Business and Financial Condition
We have no drug candidates approved for commercial sale, and we expect to continue to generate net losses as we work to evaluate strategic alternatives
After discontinuing development, Quince expects no meaningful revenue, continued losses, and an accumulated deficit that reached $460.5 million.
- NewRisks Relating to Our Business and Financial Condition
There are numerous risks and uncertainties, and we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to execute a strategic transaction, such as a reverse merger
Quince has substantial doubt about continuing as a going concern and may lack funding to complete a strategic transaction despite $20.4 million raised after year-end.
- NewRisks Relating to Our Business and Financial Condition
We may become a “shell company” in the future, which would significantly limit our flexibility to raise capital, reduce the liquidity of our securities, and adversely affect our stockholders
Disposing of assets or restructuring could make Quince an SEC shell company, restricting capital raising, security resales, equity compensation, and investor support.
- NewRisks Relating to Our Business and Financial Condition
We have and may be required to make milestone payments to the EryDel shareholders pursuant to the terms of the EryDel Acquisition or with our development and commercialization of eDSP, which could adversely affect the overall profitability of eDSP, if approved
EryDel shareholders may receive up to $485 million in milestone payments, potentially requiring financing and reducing eDSP profitability if approved.
- NewRisks Relating to Legal Compliance Matters
our preclinical, clinical and commercial materials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research, manufacturing or testing
Reliance on CROs, investigators, data organizations, medical institutions, and manufacturers could cause trial, research, manufacturing, testing, or compliance failures.
- NewRisks Relating to Legal Compliance Matters
information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts
Complex international anti-bribery, sunshine, professional-conduct, and healthcare rules could expose Quince to challenges, penalties, fines, imprisonment, and compliance costs.
- NewRisks Relating to Our Intellectual Property
and commercialize drug candidates similar or identical to ours, and the value of such assets may be adversely affected
Changing patent laws, invalid or unenforceable patents, and allowing patents to lapse while conserving cash could reduce protection and asset value.
- NewRisks Relating to Our Intellectual Property
We have applied for patents covering aspects of our drug candidates and device and their uses that we deem appropriate. However, such patent coverage may not be sufficient to prevent substantial competition
Patent applications may fail to protect Quince’s drug candidates, devices, methods, or proprietary technologies against competitors.
- NewRisks Relating to Our Intellectual Property
countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing drug candidates in those countries
Foreign patent laws, delayed filings, prior art, or confidentiality breaches could prevent protection for Quince’s research and development output.
- NewRisks Relating to Our Intellectual Property
unenforceable, we may incur substantial monetary damages, encounter significant delays in bringing our drug candidates to market and be precluded from manufacturing or selling our drug candidates
- NewRisks Relating to Our Intellectual Property
publications in the scientific literature often lag behind actual discoveries
- NewRisks Relating to Our Intellectual Property
whether we may experience patent office interruption or delays to our ability to timely secure patent coverage to our drug candidates
- NewRisks Relating to Owning Our Common Stock
ineffectiveness of our disclosure controls or internal controls
- NewRisks Relating to Owning Our Common Stock
Our outstanding warrants include put rights upon the occurrence of a fundamental transaction, which could make it difficult for us to complete a fundamental transaction that would otherwise be beneficial to our stockholders
- NewRisks Relating to Owning Our Common Stock
requiring advance notification of stockholder nominations and proposals
- NewRisks Relating to Owning Our Common Stock
we may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents
Dropped
- DroppedRisks Relating to Our Business
We are substantially dependent on the success of our lead drug candidate, eDSP
Success depended heavily on developing and commercializing eDSP after the Phase 3 ATTeST trial missed its primary endpoint.
- DroppedRisks Relating to Our Business
We have no drug candidates approved for commercial sale, we have never generated any revenue from sales, and we may never be profitable
Quince had no approved products, no sales revenue, persistent losses, and a $376.5 million accumulated deficit.
- DroppedRisks Relating to Our Business
We expect to explore partnership and licensing opportunities to support the future development of eDSP and other drug candidates. We may also encounter other unforeseen expenses, difficulties, complications, delays and other known and unknown challenges as we pursue our current strategic direction
Partnerships, licensing, unforeseen expenses, delays, and continued development spending could prevent revenue or sustainable profitability.
- DroppedRisks Relating to Our Business
If we are unable to continue as a going concern, we may have to cease operations and liquidate our assets. We may receive less than the value at which those assets are carried on our financial statements, and investors may lose all or a part of their investment
Failure to continue as a going concern could force liquidation, with investors losing some or all of their investment.
- DroppedRisks Relating to Our Business
If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any drug candidates we may develop and for which we obtain approval, we may not be successful in commercializing those drug candidates if and when they are approved
Quince lacked sales and marketing capabilities and might have needed third parties to commercialize any approved drug.
- DroppedRisks Relating to Our Business
We may encounter difficulties in managing our growth and expanding our operations successfully
Expansion of development, regulatory, manufacturing, compliance, and administrative operations could strain management and resources.
- DroppedRisks Related to the Development of Our Drug Candidates
The Phase 3 NEAT clinical trial of eDSP for A-T is being conducted under a protocol negotiated with FDA by EryDel and our execution of the trial may be slow, may not be successful, and may not result in NDA approval, with adverse results for our business and share price
- DroppedRisks Related to the Development of Our Drug Candidates
We will incur additional costs and may experience delays in completing, or ultimately be unable to complete, the development and commercialization of our drug candidates
- DroppedRisks Related to the Development of Our Drug Candidates
Our drug candidates may cause or have attributed to them undesirable side effects or have other properties that delay or prevent their regulatory approval or limit their commercial potential
- DroppedRisks Related to the Development of Our Drug Candidates
Clinical trials of our drug candidates may not uncover all possible AEs that patients may experience
- DroppedRisks Related to the Development of Our Drug Candidates
If we are not able to successfully demonstrate a favorable differentiation between eDSP and currently available corticosteroids, our business would be harmed and our ability to generate revenue from that class of drugs would be severely impaired
The NEAT Phase 3 trial could be delayed, fail, or lose FDA support, preventing NDA approval.
- DroppedRisks Related to the Development of Our Drug Candidates
Interim, top-line and preliminary data from our future clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
Clinical development, manufacturing, regulatory review, and commercialization could incur delays, added costs, or failure.
- DroppedRisks Related to the Development of Our Drug Candidates
be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our clinical studies
Adverse effects from drug candidates could halt trials, delay approval, or limit commercial potential.
- DroppedRisks Related to the Development of Our Drug Candidates
Even if we obtain regulatory approval for a drug candidate, it will remain subject to extensive ongoing regulatory review and requirements
Limited clinical-trial populations and exposure could fail to reveal all adverse events.
- DroppedRisks Related to the Development of Our Drug Candidates
A Fast Track designation by the FDA, such as the Fast Track designations received for eDSP, does not guarantee marketing approval and may not lead to a faster development, regulatory review or approval process
Failure to differentiate eDSP from generic corticosteroids could impair reimbursement, utilization, and revenue prospects.
- DroppedRisks Related to the Development of Our Drug Candidates
We may be unable to obtain and retain orphan drug designations for some of our drug candidates or to maintain the benefits associated with orphan drug designation status, including market exclusivity, which may cause our revenue, if any, to be reduced
Preliminary or top-line clinical data could materially change after further review, auditing, and verification.
- DroppedRisks Relating to Our Financial Position
We are a clinical stage biotechnology company and have a limited history operating a newly acquired business, which may make it difficult to evaluate the prospects for our future viability
- DroppedRisks Relating to Our Financial Position
The terms of the EIB Loan place restrictions on our operating and financial flexibility
- DroppedRisks Relating to Regulatory Review and Approval of Our Drug Candidates and Other Legal Compliance Matters
We cannot be certain that the FDA or foreign regulatory authorities will permit us to proceed with any current or future proposed clinical trial designs. Our drug candidates may not receive regulatory approval, and without regulatory approval we will not be able to market our drug candidates
- DroppedRisks Relating to Regulatory Review and Approval of Our Drug Candidates and Other Legal Compliance Matters
We currently have no drug candidates approved for sale and we cannot guarantee that we will ever have marketable drug candidates. Our ability to generate revenue related to sales, if ever, will depend on the successful development and regulatory approval of our drug candidates
- DroppedRisks Relating to Regulatory Review and Approval of Our Drug Candidates and Other Legal Compliance Matters
other healthcare funding, which may adversely affect customer demand and affordability for our drug candidates and, accordingly, the results of our financial operations
- DroppedRisks Relating to Regulatory Review and Approval of Our Drug Candidates and Other Legal Compliance Matters
manufactured in accordance with the guidelines on GMP and in a GMP licensed facility, which can be subject to GMP inspections
- DroppedRisks Relating to Regulatory Review and Approval of Our Drug Candidates and Other Legal Compliance Matters
Our ability to successfully commercialize any drugs that we develop depends in part on the extent to which coverage and adequate reimbursement are available from government health administration authorities, private health insurers, and other organizations
- DroppedRisks Relating to Regulatory Review and Approval of Our Drug Candidates and Other Legal Compliance Matters
the market. Many EU Member States also periodically review their reimbursement procedures for medicinal products, which could have an adverse impact on reimbursement status
- DroppedRisks Related to the Production and Manufacturing of our Drug Candidates and Future Products
Our production capacity could prove insufficient for our needs
- DroppedRisks Related to the Production and Manufacturing of our Drug Candidates and Future Products
We are dependent on third parties for the supply of various materials that are necessary to produce our drug candidates for clinical trials
- DroppedRisks Related to the Production and Manufacturing of our Drug Candidates and Future Products
Our manufacturing facilities are subject to significant government regulations and approvals. If we or our third-party manufacturers fail to comply with these regulations or maintain these approvals, our business will be materially harmed
- DroppedRisks Related to the Production and Manufacturing of our Drug Candidates and Future Products
Our production costs may be higher than we currently estimate
- DroppedRisks Related to the Production and Manufacturing of our Drug Candidates and Future Products
If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our drug candidates, if approved
- DroppedRisks Related to the Production and Manufacturing of our Drug Candidates and Future Products
The United Kingdom’s withdrawal from the EU may have a negative effect on global economic conditions, financial markets and our business, which could reduce the price of our common stock
- DroppedRisks Related to the Production and Manufacturing of our Drug Candidates and Future Products
end of procedure outcome from the mutual recognition or decentralized procedures are considered to be authorizations for the purposes of the IRP
- DroppedRisks Related to the Production and Manufacturing of our Drug Candidates and Future Products
Any collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize potential future drug candidates
- DroppedRisks Relating to Our Intellectual Property
Should any of these events occur, they would significantly harm our business, results of operations and prospects
- DroppedRisks Relating to Our Intellectual Property
proliferation of patents, and it is not always clear to industry participants, including us, which patents cover various types of drug candidates or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform
- DroppedRisks Relating to Our Intellectual Property
We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products
- DroppedRisks Relating to Our Intellectual Property
In the future, we may need to obtain licenses of third-party technology that may not be available to us or are available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated
- DroppedRisks Relating to Our Intellectual Property
Intellectual property rights do not necessarily address all potential threats to our competitive advantage
- DroppedRisks Relating to Our Intellectual Property
We may not be able to protect our intellectual property rights throughout the world
- DroppedRisks Relating to Our Intellectual Property
Patent terms may be inadequate to protect our competitive position on our drug candidates for an adequate amount of time, and if we do not obtain patent term extension for our drug candidates, our business may be materially harmed
- DroppedRisks Relating to Our Intellectual Property
If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
- DroppedRisks Relating to Our Intellectual Property
We may not be successful in obtaining or maintaining necessary rights to our drug candidates through acquisitions and in-licenses
- DroppedRisks Relating to Owning Our Common Stock
Moreover, we have also registered under the Securities Act shares of common stock that we may issue under our equity compensation plans
- DroppedRisks Relating to Owning Our Common Stock
We have in the past and may in the future fail to meet the requirements for continued listing on Nasdaq. If we fail to maintain compliance with the minimum listing requirements, our common stock may be delisted, which could have a material adverse effect on the liquidity of our common stock
- DroppedRisks Relating to Owning Our Common Stock
of taxable income for tax years beginning January 1, 2018. NOLs generated in Italy are subject to Italian tax laws and deductibility of such Italian NOLs may be limited to 80% of taxable income
Reworded
- 85% rewrittenRisks Relating to Legal Compliance Matters
Any failure to comply with any of these obligations may impact our activities in the EEA, the renewal of our existing CE Certificates of Conformity and future conformity assessment activities
No substantive change; the risk continues to cover manufacturing problems, recalls, and enforcement affecting CE Certificates of Conformity.
- 82% rewrittenRisks Relating to Our Intellectual Property
If we are sued for patent infringement, we would need to demonstrate that our drug candidates or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity or unenforceability is difficult
No substantive change; the risk continues to cover costly patent litigation and difficulty proving patents invalid or unenforceable.
- 79% rewrittenRisks Relating to Legal Compliance Matters
The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act(collectively, the “PPACA”) substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry
No substantive change; the risk continues to cover PPACA challenges and future healthcare reforms affecting commercialization and sales.
- 78% rewrittenRisks Relating to Owning Our Common Stock
Our charter documents and Delaware law could prevent a takeover that stockholders consider favorable and could also reduce the market price of our stock
No substantive change; takeover defenses remain materially the same, including the classified board and preferred-stock authority.
- 77% rewrittenRisks Relating to Owning Our Common Stock
Future sales of our common stock in the public market could cause our share price to fall
Adds that shares registered under equity compensation plans could increase future public-market supply and pressure the stock price.
- 74% rewrittenRisks Relating to Owning Our Common Stock
Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law
No substantive change; the disclosure retains broad Delaware-law indemnification and expense-advancement protections for directors and officers.
- 69% rewrittenRisks Relating to Owning Our Common Stock
Our ability to utilize our federal net operating loss and tax credit carryforwards may be limited
Adds that Italian NOLs are subject to Italian tax law and an 80% taxable-income deductibility limit.
- 60% rewrittenRisks Relating to Our Intellectual Property
We cannot ensure that patent rights relating to inventions described and claimed in our pending patent applications will issue or that patents based on our patent applications will not be challenged and rendered invalid and/or unenforceable
No substantive change; the disclosure still addresses uncertainty over patent issuance, scope, validity, circumvention, and enforcement.
- 57% rewrittenRisks Relating to Our Business and Financial Condition
We may not be able to manage our business effectively if we are unable to attract and retain key personnel and consultants, and the loss of such persons could negatively impact the operations of the company
- 50% rewrittenRisks Relating to Owning Our Common Stock
The market price of our common stock is likely to be volatile and could fluctuate or decline, resulting in a substantial loss of your investment
- 44% rewrittenRisks Relating to Our Intellectual Property
Our success will depend in part on our ability to operate without infringing the intellectual property rights of third parties. We cannot guarantee that our drug candidates, or manufacture or use of our drug candidates, will not infringe third-party patents
- 30% rewrittenRisks Relating to Legal Compliance Matters
If we fail to comply with healthcare laws, we could face substantial penalties and our business, operations and financial condition could be adversely affected
- 30% rewrittenRisks Relating to Legal Compliance Matters
Our insurance policies are expensive and only protect us from some business risks, which will leave us exposed to significant uninsured liabilities
- 28% rewrittenRisks Relating to Our Business and Financial Condition
Our failure to maintain certain tax benefits applicable to Italian biotechnology companies may adversely affect our results of operations, our cash flows and our financial condition
All 50 risk factors
Headings as the filing states them, in filing order.
Risks Relating to Our Business and Financial Condition
- 01Nasdaq may delist our securities from its exchange, which could adversely affect our ability to execute a strategic transaction and limit our stockholders’ liquidityNew
- 02requirements, there is no guarantee that we will be able to regain compliance. In addition, as of December 31, 2025, our total stockholders’ deficit was approximately $35.7 millionNew
- 03If we are unable to execute a strategic transaction, may be required to pursue a reorganization proceeding under applicable bankruptcy or insolvency laws, including under Chapters 7 or 11 of the U.S. Bankruptcy CodeNew
- 04We have no drug candidates approved for commercial sale, and we expect to continue to generate net losses as we work to evaluate strategic alternativesNew
- 05There are numerous risks and uncertainties, and we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to execute a strategic transaction, such as a reverse mergerNew
- 06We may become a “shell company” in the future, which would significantly limit our flexibility to raise capital, reduce the liquidity of our securities, and adversely affect our stockholdersNew
- 07We have and may be required to make milestone payments to the EryDel shareholders pursuant to the terms of the EryDel Acquisition or with our development and commercialization of eDSP, which could adversely affect the overall profitability of eDSP, if approvedNew
- 08We may be exposed to a variety of international risks that could materially adversely affect our business
- 09Any of these factors could harm our ongoing international clinical operations and supply chain, as well as any future international expansion and operations and, consequently, our business, financial condition, prospects and results of operations
- 10We may not be able to manage our business effectively if we are unable to attract and retain key personnel and consultants, and the loss of such persons could negatively impact the operations of the company57% rewritten
- 11Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading, which could significantly harm our business
- 12Our financial results have been in the past and may in the future be adversely affected by impairment charges from the recording of goodwill and intangible assets
- 13Unstable market and global economic conditions, including adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions, may have adverse consequences on our business, financial condition and stock price
- 14Our failure to maintain certain tax benefits applicable to Italian biotechnology companies may adversely affect our results of operations, our cash flows and our financial condition28% rewritten
Risks Relating to Legal Compliance Matters
- 15Changes in healthcare law and implementing regulations, as well as changes in healthcare policy, may impact our business in ways that we cannot currently predict, and may have a significant adverse effect on our business and results of operations
- 16The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act(collectively, the “PPACA”) substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry79% rewritten
- 17our preclinical, clinical and commercial materials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research, manufacturing or testingNew
- 18If we fail to comply with healthcare laws, we could face substantial penalties and our business, operations and financial condition could be adversely affected30% rewritten
- 19information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance effortsNew
- 20If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
- 21Our business activities may be subject to the FCPA and similar anti-bribery and anti-corruption laws
- 22The manufacture of our products requires strict adherence to regulatory requirements governing medical devices and if we or our suppliers encounter problems our business could suffer
- 23Any failure to comply with any of these obligations may impact our activities in the EEA, the renewal of our existing CE Certificates of Conformity and future conformity assessment activities85% rewritten
- 24Our insurance policies are expensive and only protect us from some business risks, which will leave us exposed to significant uninsured liabilities30% rewritten
Risks Relating to Our Intellectual Property
- 25and commercialize drug candidates similar or identical to ours, and the value of such assets may be adversely affectedNew
- 26We have applied for patents covering aspects of our drug candidates and device and their uses that we deem appropriate. However, such patent coverage may not be sufficient to prevent substantial competitionNew
- 27countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing drug candidates in those countriesNew
- 28Our success will depend in part on our ability to operate without infringing the intellectual property rights of third parties. We cannot guarantee that our drug candidates, or manufacture or use of our drug candidates, will not infringe third-party patents44% rewritten
- 29If we are sued for patent infringement, we would need to demonstrate that our drug candidates or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity or unenforceability is difficult82% rewritten
- 30unenforceable, we may incur substantial monetary damages, encounter significant delays in bringing our drug candidates to market and be precluded from manufacturing or selling our drug candidatesNew
- 31publications in the scientific literature often lag behind actual discoveriesNew
- 32Maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
- 33We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers. If we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of our technology and drug candidate could be significantly diminished
- 34Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties
- 35Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our intellectual property
- 36We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property
- 37We cannot ensure that patent rights relating to inventions described and claimed in our pending patent applications will issue or that patents based on our patent applications will not be challenged and rendered invalid and/or unenforceable60% rewritten
- 38whether we may experience patent office interruption or delays to our ability to timely secure patent coverage to our drug candidatesNew
Risks Relating to Owning Our Common Stock
- 39The market price of our common stock is likely to be volatile and could fluctuate or decline, resulting in a substantial loss of your investment50% rewritten
- 40ineffectiveness of our disclosure controls or internal controlsNew
- 41We may be subject to securities class action and stockholder derivative actions. These, and potential similar or related litigation, could result in substantial damages and may divert management’s time and attention from our business and adversely impact our business, results of operations and financial condition
- 42Future sales of our common stock in the public market could cause our share price to fall77% rewritten
- 43We have never paid dividends on our common stock and we do not intend to pay dividends for the foreseeable future. Consequently, any gains from an investment in our common stock will likely depend on whether the price of our common stock increases
- 44Our stockholders may realize little or no value from the divestiture of our legacy assets, and as a result our stock price may decline, we could be subject to litigation, and our business may be adversely affected
- 45Our outstanding warrants include put rights upon the occurrence of a fundamental transaction, which could make it difficult for us to complete a fundamental transaction that would otherwise be beneficial to our stockholdersNew
- 46Our charter documents and Delaware law could prevent a takeover that stockholders consider favorable and could also reduce the market price of our stock78% rewritten
- 47requiring advance notification of stockholder nominations and proposalsNew
- 48Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law74% rewritten
- 49we may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agentsNew
- 50Our ability to utilize our federal net operating loss and tax credit carryforwards may be limited69% rewritten
Other Quince Therapeutics 10-Ks
- FY2024 10-K risk factors75 risks
Quince Therapeutics depends entirely on the clinical and commercial success of its lead drug candidate, eDSP, for A-T.
Filed Mar 24, 2025
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.